Julianne Hull is currently CEO of WenStar Enterprises a company she formed to provide training and consultancy to the pharmaceutical industry primarily in the areas of clinical outsourcing and clinical operations but also in other areas of clinical development.
With over 26 years experience in clinical development Julianne has successfully held global leadership roles in vendor management/outsourcing and clinical operations for several large and medium pharmaceutical companies (Pfizer, Wyeth, Marion Merrell Dow, Biogen Idec and Ipsen). In these roles she has been an accomplished manager and motivator of staff based in China, India, Japan, Europe and US.
Within Wyeth Julianne developed, implemented and ran the key cross functional governance body to drive successful delivery for inspection ready clinical trials. Responsible for the strategic development and implementation of unique, quality and cost-effective methods of outsourcing Clinical Data Management led to the establishment of the ground-breaking Wyeth Accenture strategic alliance in 2003. Julianne had business and operational oversight of the Wyeth/Accenture alliance through the acquisition of Wyeth by Pfizer in 2010. For Wyeth, Biogen Idec and Ipsen Julianne had critical roles in the development and implementation of effective service provider governance.
Julianne is an active member of the DIA. She was the program chair of the DIA 2015 Clinical Forum in Paris, April 2015. She received a DIA award for service to the pharmaceutical industry in 2013. Julianne has been on the advisory board of the Partnerships conference run by Informa since 2006. Julianne is also an honorary life member of the ACDM.
Good Clinical Practice is the core to running all clinical trials. The guidelines were revised in 2016 and put into law in 2017 and 2018.